Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats.

ABSTRACT: Our objective was to provide preliminary clinical and laboratory data and the minimum effective dose for long-term (≥ 7 mo) treatment of feline allergic pruritus with oclacitinib. We studied 14 privately owned cats with pruritic allergic dermatitis controlled with oclacitinib treatment. Clinical data and results of blood testing (at the onset and at least once thereafter) during treatment were retrospectively evaluated. The median initial dosage of oclacitinib was 1.1 mg/kg q12h. In 7 animals, the maintenance dose could be reduced by ≥ 50%, usually after 15 d of treatment. The median duration of treatment was 15.5 mo. An FeLV-FIV test was conducted in 10 cats and all were negative. During treatment, 4 cats had non-dermatologic disorders that resolved without changing the oclacitinib dosing

SUBMITTER: Urkiola A 

PROVIDER: S-EPMC12330796 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature